Roche anti-TIGIT cancer immunotherapy fails in first late-stage clinical trial

By STAT News
| March 30, 2022

Roche said Wednesday that an experimental cancer immunotherapy directed against a target called TIGIT failed to slow the progression of a less common but aggressive type of lung cancer.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...